Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL

Background: The study RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that Losartan was more effective lo reduce the progression of kidney disease in diabetic patients with proteinuria and a reduction in glomerular filtration rate. Aim: To perform a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	González F,Fernando, Fuentes C,Verónica, Castro H,Catalina, Santelices L,Juan Pablo, Lorca H,Eduardo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2009
Materias:	Diabetic nephopathy Diabetes mellitus, Type 2 Losartan
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000500006
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872009000500006
record_format	dspace
spelling	oai:scielo:S0034-988720090005000062009-07-17Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAALGonzález F,FernandoFuentes C,VerónicaCastro H,CatalinaSantelices L,Juan PabloLorca H,Eduardo Diabetic nephopathy Diabetes mellitus, Type 2 Losartan Background: The study RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that Losartan was more effective lo reduce the progression of kidney disease in diabetic patients with proteinuria and a reduction in glomerular filtration rate. Aim: To perform a cost benefit analysis of Losartan use from provider and payer points of view. Material and methods: Published data of the RENAAL study was analyzed. The costs of the use or not use of Losartan in patients with diabetic nephropathy were compared in terms of total costs of the disease including medications, hospital admissions for myocardial infarction, cerebrovascular accidents and congestive cardiac failure and the costs of chronic hemodialysis. Results: The reduction in antihypertensive medication use, hospital admissions, and the delay in dialysis requirement from a mean of 65 to 79 months induced by Losartan use, results in net savings of $7,576,135 per patient, at 3.5 years of intervention. The figure does not change using different sensitivity scenarios. Conclusions: The eventual use of Losartan in type 2 diabetic patients results in important savings.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.137 n.5 20092009-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000500006es10.4067/S0034-98872009000500006
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Diabetic nephopathy Diabetes mellitus, Type 2 Losartan
spellingShingle	Diabetic nephopathy Diabetes mellitus, Type 2 Losartan González F,Fernando Fuentes C,Verónica Castro H,Catalina Santelices L,Juan Pablo Lorca H,Eduardo Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
description	Background: The study RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that Losartan was more effective lo reduce the progression of kidney disease in diabetic patients with proteinuria and a reduction in glomerular filtration rate. Aim: To perform a cost benefit analysis of Losartan use from provider and payer points of view. Material and methods: Published data of the RENAAL study was analyzed. The costs of the use or not use of Losartan in patients with diabetic nephropathy were compared in terms of total costs of the disease including medications, hospital admissions for myocardial infarction, cerebrovascular accidents and congestive cardiac failure and the costs of chronic hemodialysis. Results: The reduction in antihypertensive medication use, hospital admissions, and the delay in dialysis requirement from a mean of 65 to 79 months induced by Losartan use, results in net savings of $7,576,135 per patient, at 3.5 years of intervention. The figure does not change using different sensitivity scenarios. Conclusions: The eventual use of Losartan in type 2 diabetic patients results in important savings.
author	González F,Fernando Fuentes C,Verónica Castro H,Catalina Santelices L,Juan Pablo Lorca H,Eduardo
author_facet	González F,Fernando Fuentes C,Verónica Castro H,Catalina Santelices L,Juan Pablo Lorca H,Eduardo
author_sort	González F,Fernando
title	Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
title_short	Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
title_full	Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
title_fullStr	Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
title_full_unstemmed	Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL
title_sort	cálculo del impacto económico para chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio renaal
publisher	Sociedad Médica de Santiago
publishDate	2009
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000500006
work_keys_str_mv	AT gonzalezffernando calculodelimpactoeconomicoparachiledelusodelosartanendiabeticostipo2connefropatiadiabeticabasadoenresultadosdelestudiorenaal AT fuentescveronica calculodelimpactoeconomicoparachiledelusodelosartanendiabeticostipo2connefropatiadiabeticabasadoenresultadosdelestudiorenaal AT castrohcatalina calculodelimpactoeconomicoparachiledelusodelosartanendiabeticostipo2connefropatiadiabeticabasadoenresultadosdelestudiorenaal AT santelicesljuanpablo calculodelimpactoeconomicoparachiledelusodelosartanendiabeticostipo2connefropatiadiabeticabasadoenresultadosdelestudiorenaal AT lorcaheduardo calculodelimpactoeconomicoparachiledelusodelosartanendiabeticostipo2connefropatiadiabeticabasadoenresultadosdelestudiorenaal
_version_	1718436442355531776

Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL

Ejemplares similares